 <h1>Brigatinib Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><h2>In Summary</h2><p><b>Commonly reported side effects of brigatinib include:</b> asthenia, blurred vision, cough, decreased visual acuity, diplopia, dyspnea, hyperglycemia, hypertension, increased amylase, increased creatine phosphokinase in blood specimen, increased serum lipase, myalgia, and visual disturbance. <b>Other side effects include:</b> interstitial pulmonary disease, pneumonitis, and bradycardia.  See below for a comprehensive list of adverse effects.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to brigatinib: oral tablet</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, brigatinib may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking brigatinib:</p><p>
<i>More common</i>
</p><ul>
<li>Back pain</li>
<li>blurred vision</li>
<li>burning, crawling, itching, numbness, prickling, "pins and needles", or tingling feelings</li>
<li>chest pain or tightness</li>
<li>chills</li>
<li>confusion</li>
<li>cough</li>
<li>decreased appetite</li>
<li>difficulty in moving</li>
<li>dizziness</li>
<li>dry mouth</li>
<li>fever</li>
<li>flushed, dry skin</li>
<li>fruit-like breath odor</li>
<li>headache</li>
<li>hoarseness</li>
<li>increased hunger</li>
<li>increased thirst</li>
<li>increased urination</li>
<li>joint pain</li>
<li>loss of appetite</li>
<li>lower back or side pain</li>
<li>muscle pain, tenderness, or weakness</li>
<li>nausea</li>
<li>nervousness</li>
<li>pain in the arms or legs</li>
<li>painful or difficult urination</li>
<li>pale skin</li>
<li>pounding in the ears</li>
<li>skin rash or itching</li>
<li>slow or fast heartbeat</li>
<li>sneezing</li>
<li>sore throat</li>
<li>stomach pain or tenderness</li>
<li>sweating</li>
<li>swollen joints</li>
<li>thickening of bronchial secretions</li>
<li>trouble breathing</li>
<li>troubled breathing with exertion</li>
<li>unexplained weight loss</li>
<li>unusual bleeding or bruising</li>
<li>unusual tiredness or weakness</li>
<li>vomiting</li>
<li>weakness in the arms, hands, legs, or feet</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>General feeling of discomfort or illness</li>
<li>thickening of bronchial secretions</li>
</ul><p>
<i>Rare</i>
</p><ul>
<li>Fast heartbeat</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of brigatinib may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Decreased appetite</li>
<li>diarrhea</li>
<li>difficulty having a bowel movement</li>
<li>trouble sleeping</li>
</ul><p>
<!-- end oral tablet --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to brigatinib: oral tablet</i></p><h3>General</h3><p>-The most common adverse reactions (25% or more) were nausea, diarrhea, fatigue, cough, and headache.</p>
<p>-Serious adverse reactions occurred in 38% to 40% of patients; fatal cases were reported in 3.7% of patients and consisted of pneumonia (2 patients), sudden death, dyspnea, respiratory failure, pulmonary embolism, bacterial meningitis, and urosepsis (1 patient each).<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): Increased AST (65%), increased ALT (40%), increased alkaline phosphatase (29%)<sup>[Ref]</sup></p><h3>Endocrine</h3><p><b>Very common</b> (10% or more): Hyperglycemia (49%)<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Increased creatine phosphokinase (48%), muscle spasms (17%), back pain (15%), myalgia/musculoskeletal pain (15%), arthralgia (14%), pain in extremity (11%)<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Increased lipase (45%), nausea (40%), increased amylase (39%), diarrhea (38%), vomiting (24%), constipation (19%), abdominal pain and distension/epigastric discomfort (17%)<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Anemia (40%), lymphopenia (27%)<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Fatigue/asthenia (36%), pyrexia (14%)<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Cough (34%), dyspnea/exertional dyspnea (27%)</p>
<p><b>Common</b> (1% to 10%): interstitial lung disease/pneumonitis, hypoxia<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache/sinus headache (28%), peripheral sensory neuropathy/paresthesia (13%)<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Rash (exfoliative, pruritic, pustular)/acneiform dermatitis (24%)<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Decreased phosphorous (23%), decreased appetite (22%)<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Very common</b> (10% or more): Prolonged activated partial thromboplastin time (22%), hypertension (21%)</p>
<p><b>Common</b> (1% to 10%): Bradycardia<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Very common</b> (10% or more): Insomnia (11%)<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Very common</b> (10% or more): Visual disturbance (10%), pneumonia (10%)<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Alunbrig (brigatinib)." Ariad Pharmaceuticals Inc, Cambridge, MA. </p></div>
<div class="more-resources" id="moreResources">
<h2>More about brigatinib</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Español</li>
<li>Drug class: multikinase inhibitors</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Brigatinib &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Alunbrig</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Non-Small Cell Lung Cancer</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to brigatinib: oral tablet</i></p><h3>General</h3><p>-The most common adverse reactions (25% or more) were nausea, diarrhea, fatigue, cough, and headache.</p><p>-Serious adverse reactions occurred in 38% to 40% of patients; fatal cases were reported in 3.7% of patients and consisted of pneumonia (2 patients), sudden death, dyspnea, respiratory failure, pulmonary embolism, bacterial meningitis, and urosepsis (1 patient each).<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): Increased AST (65%), increased ALT (40%), increased alkaline phosphatase (29%)<sup>[Ref]</sup></p><h3>Endocrine</h3><p><b>Very common</b> (10% or more): Hyperglycemia (49%)<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Increased creatine phosphokinase (48%), muscle spasms (17%), back pain (15%), myalgia/musculoskeletal pain (15%), arthralgia (14%), pain in extremity (11%)<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Increased lipase (45%), nausea (40%), increased amylase (39%), diarrhea (38%), vomiting (24%), constipation (19%), abdominal pain and distension/epigastric discomfort (17%)<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Anemia (40%), lymphopenia (27%)<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Fatigue/asthenia (36%), pyrexia (14%)<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Cough (34%), dyspnea/exertional dyspnea (27%)</p><p><b>Common</b> (1% to 10%): interstitial lung disease/pneumonitis, hypoxia<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache/sinus headache (28%), peripheral sensory neuropathy/paresthesia (13%)<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Rash (exfoliative, pruritic, pustular)/acneiform dermatitis (24%)<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Decreased phosphorous (23%), decreased appetite (22%)<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Very common</b> (10% or more): Prolonged activated partial thromboplastin time (22%), hypertension (21%)</p><p><b>Common</b> (1% to 10%): Bradycardia<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Very common</b> (10% or more): Insomnia (11%)<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Very common</b> (10% or more): Visual disturbance (10%), pneumonia (10%)<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Alunbrig (brigatinib)." Ariad Pharmaceuticals Inc, Cambridge, MA. </p><h2>More about brigatinib</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Español</li>
<li>Drug class: multikinase inhibitors</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Brigatinib &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Non-Small Cell Lung Cancer</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>